86 related articles for article (PubMed ID: 9551957)
1. In SCID-hu mice, passive transfer of a humanized antibody prevents infection and atrophic change of medulla in human thymic implant due to intravenous inoculation of primary HIV-1 isolate.
Okamoto Y; Eda Y; Ogura A; Shibata S; Amagai T; Katsura Y; Asano T; Kimachi K; Makizumi K; Honda M
J Immunol; 1998 Jan; 160(1):69-76. PubMed ID: 9551957
[TBL] [Abstract][Full Text] [Related]
2. Divergent effects of chronic HIV-1 infection on human thymocyte maturation in SCID-hu mice.
Kollmann TR; Kim A; Pettoello-Mantovani M; Hachamovitch M; Rubinstein A; Goldstein MM; Goldstein H
J Immunol; 1995 Jan; 154(2):907-21. PubMed ID: 7814892
[TBL] [Abstract][Full Text] [Related]
3. Construction and characterization of chimeric and humanized forms of a broadly neutralizing monoclonal antibody to HIV-1.
Major JG; Liou RS; Sun LK; Yu LM; Starnes SM; Fung MS; Chang TW; Chang NT
Hum Antibodies Hybridomas; 1994; 5(1-2):9-17. PubMed ID: 7858187
[TBL] [Abstract][Full Text] [Related]
4. Defining antibody protection against HIV-1 transmission in Hu-PBL-SCID mice.
Koup RA; Safrit JT; Weir R; Gauduin MC
Semin Immunol; 1996 Aug; 8(4):263-8. PubMed ID: 8883150
[TBL] [Abstract][Full Text] [Related]
5. hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120.
Safrit JT; Fung MS; Andrews CA; Braun DG; Sun WN; Chang TW; Koup RA
AIDS; 1993 Jan; 7(1):15-21. PubMed ID: 7680205
[TBL] [Abstract][Full Text] [Related]
6. Ex vivo neutralization of HIV-1 quasi-species by a broadly reactive humanized monoclonal antibody KD-247.
Matsushita S; Takahama S; Shibata J; Kimura T; Shiozaki K; Eda Y; Koito A; Murakami T; Yoshimura K
Hum Antibodies; 2005; 14(3-4):81-8. PubMed ID: 16720978
[TBL] [Abstract][Full Text] [Related]
7. Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guérin vector candidate vaccine for human immunodeficiency virus type 1 in small animals.
Honda M; Matsuo K; Nakasone T; Okamoto Y; Yoshizaki H; Kitamura K; Sugiura W; Watanabe K; Fukushima Y; Haga S; Katsura Y; Tasaka H; Komuro K; Yamada T; Asano T; Yamazaki A; Yamazaki S
Proc Natl Acad Sci U S A; 1995 Nov; 92(23):10693-7. PubMed ID: 7479867
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of replication of primary HIV-1 isolates in huPBL-NOD/Scid mice by antibodies from HIV-1 infected patients.
Steyaert S; Heyndrickx L; Verhoye L; Vermoesen T; Donners H; Fransen K; Van Wanzeele F; Vandergucht B; Vanham G; Leroux-Roels G; Vanlandschoot P
Antiviral Res; 2007 Aug; 75(2):129-38. PubMed ID: 17379323
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy using a simian virus 40-derived vector inhibits the development of in vivo human immunodeficiency virus type 1 infection of severe combined immunodeficiency mice implanted with human fetal thymic and liver tissue.
Goldstein H; Pettoello-Mantovani M; Anderson CM; Cordelier P; Pomerantz RJ; Strayer DS
J Infect Dis; 2002 May; 185(10):1425-30. PubMed ID: 11992277
[TBL] [Abstract][Full Text] [Related]
10. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1.
Gauduin MC; Parren PW; Weir R; Barbas CF; Burton DR; Koup RA
Nat Med; 1997 Dec; 3(12):1389-93. PubMed ID: 9396610
[TBL] [Abstract][Full Text] [Related]
11. Pertussis toxin B-oligomer inhibits HIV infection and replication in hu-PBL-SCID mice.
Lapenta C; Spada M; Santini SM; Racca S; Dorigatti F; Poli G; Belardelli F; Alfano M
Int Immunol; 2005 Apr; 17(4):469-75. PubMed ID: 15746245
[TBL] [Abstract][Full Text] [Related]
12. Anti-nerve growth factor Ab abrogates macrophage-mediated HIV-1 infection and depletion of CD4+ T lymphocytes in hu-SCID mice.
Garaci E; Aquaro S; Lapenta C; Amendola A; Spada M; Covaceuszach S; Perno CF; Belardelli F
Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8927-32. PubMed ID: 12853577
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.
Shibata R; Igarashi T; Haigwood N; Buckler-White A; Ogert R; Ross W; Willey R; Cho MW; Martin MA
Nat Med; 1999 Feb; 5(2):204-10. PubMed ID: 9930869
[TBL] [Abstract][Full Text] [Related]
14. Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site.
Parren PW; Ditzel HJ; Gulizia RJ; Binley JM; Barbas CF; Burton DR; Mosier DE
AIDS; 1995 Jun; 9(6):F1-6. PubMed ID: 7662189
[TBL] [Abstract][Full Text] [Related]
15. Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope.
Zolla-Pazner S; Cohen SS; Krachmarov C; Wang S; Pinter A; Lu S
Virology; 2008 Mar; 372(2):233-46. PubMed ID: 18061228
[TBL] [Abstract][Full Text] [Related]
16. Passive immunization with a human immunodeficiency virus type 1-neutralizing monoclonal antibody in Hu-PBL-SCID mice: isolation of a neutralization escape variant.
Andrus L; Prince AM; Bernal I; McCormack P; Lee DH; Gorny MK; Zolla-Pazner S
J Infect Dis; 1998 Apr; 177(4):889-97. PubMed ID: 9534960
[TBL] [Abstract][Full Text] [Related]
17. Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha.
Lapenta C; Santini SM; Logozzi M; Spada M; Andreotti M; Di Pucchio T; Parlato S; Belardelli F
J Exp Med; 2003 Jul; 198(2):361-7. PubMed ID: 12874266
[TBL] [Abstract][Full Text] [Related]
18. Type I interferon is a powerful inhibitor of in vivo HIV-1 infection and preserves human CD4(+) T cells from virus-induced depletion in SCID mice transplanted with human cells.
Lapenta C; Santini SM; Proietti E; Rizza P; Logozzi M; Spada M; Parlato S; Fais S; Pitha PM; Belardelli F
Virology; 1999 Oct; 263(1):78-88. PubMed ID: 10544084
[TBL] [Abstract][Full Text] [Related]
19. Polygene DNA vaccine induces a high level of protective effect against HIV-vaccinia virus challenge in mice.
Shinoda K; Xin KQ; Jounai N; Kojima Y; Tamura Y; Okada E; Kawamoto S; Okuda K; Klinman D; Okuda K
Vaccine; 2004 Sep; 22(27-28):3676-90. PubMed ID: 15315847
[TBL] [Abstract][Full Text] [Related]
20. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
